This invention relates, inter alia, to an immunogenic fragment of a Neisserial Heparin Binding Antigen (NHBA) protein of Neisseria gonorrhoeae (SEQ ID NO: 1) for the prevention and treatment of Neisseria gonorrhoeae or gonococcal- or meningococcal-associated diseases and conditions. In some embodiments, the immunogenic fragment corresponds to a C-terminal fragment of the protein (SEQ ID NO: 2).

Variant factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of Neisseria meningitidis, compositions comprising such proteins, and methods of use of such proteins, are provided.

Variant factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of Neisseria meningitidis, compositions comprising such proteins, and methods of use of such proteins, are provided.

Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of N. meningitidis, and methods of use of such proteins, are provided.

Factor H binding proteins that can elicit antibodies that are bactericidal for at least one strain of N. meningitidis, and methods of use of such proteins, are provided.

Carrier proteins modified to incorporate one or more pilin glycotags and applications thereof for O-linked glycosylation are provided. In particular, a modified carrier protein comprising a carrier protein that comprises at least one GlycoTag, wherein the at least one GlycoTag is a Neisseria gonorrhoeae PglL GlycoTag (NgGlycoTag), Neisseria lactamica PglL GlycoTag (NlGlycoTag), or Neisseria shayeganii GlycoTag (NsGlycoTag), or combinations thereof is provided, together with nucleic acids and vectors encoding the modified carrier protein, host cells comprising these modofoed carrier proteins or nucleic acids encoding them, bioconjugates, methods of making bioconjugates and uses of the bioconjugates.

Carrier proteins modified to incorporate one or more pilin glycotags and applications thereof for O-linked glycosylation are provided. In particular, a modified carrier protein comprising a carrier protein that comprises at least one GlycoTag, wherein the at least one GlycoTag is a Neisseria gonorrhoeae PglL GlycoTag (NgGlycoTag), Neisseria lactamica PglL GlycoTag (NlGlycoTag), or Neisseria shayeganii GlycoTag (NsGlycoTag), or combinations thereof is provided, together with nucleic acids and vectors encoding the modified carrier protein, host cells comprising these modofoed carrier proteins or nucleic acids encoding them, bioconjugates, methods of making bioconjugates and uses of the bioconjugates.

In one aspect, the invention relates to an isolated polypeptide including the amino acid sequence of a carrier polypeptide and the amino acid sequence of an ORF2086 polypeptide. In another aspect, the invention relates to an immunogenic conjugate including ORF2086 polypeptide and a carrier polypeptide. The invention further includes immunogenic compositions and methods for inducing an immune response against Neisseria meningitidis in a mammal.

In one aspect, the invention relates to an isolated polypeptide including the amino acid sequence of a carrier polypeptide and the amino acid sequence of an ORF2086 polypeptide. In another aspect, the invention relates to an immunogenic conjugate including ORF2086 polypeptide and a carrier polypeptide. The invention further includes immunogenic compositions and methods for inducing an immune response against Neisseria meningitidis in a mammal.

The present invention relates to compositions and methods for preventing and/or treating gonorrhea. In particular, the present invention provides compositions comprising an effective amount of a commensal species of Neisseria (e.g., an effective amount of an extract of a commensal species of Neisseria), wherein such compositions are capable of inhibiting the growth of Neisseria gonorrhoeae.